Clinical Trial Update: Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating irinotecan in combination with bortezomib in children with recurrent or refractory neuroblastoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Bortezomib (bortezomib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Neuroblastoma | Phase 1 | Status: COMPLETED